Role of immunotherapy in pulmonary sarcomatoid carcinoma: review of current approaches and related biomarkers

被引：1

作者：

Ding, Kaibo ^{[1
,2
]}

Peng, Zhongsheng ^{[1
,2
]}

Xu, Yanjun ^{[1
]}

机构：

[1] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med, Dept Med Thorac Oncol, 1 East Banshan Rd, Hangzhou 310022, Zhejiang, Peoples R China

[2] Wenzhou Med Univ, Zhejiang Canc Hosp, Postgrad Training Base Alliance, Hangzhou, Zhejiang, Peoples R China

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2024年 / 16卷

关键词：

biomarkers; combination therapy; immunotherapy; pulmonary sarcomatoid carcinoma; tumor microenvironment; TUMOR MUTATIONAL BURDEN; SHOW HIGH-LEVELS; PD-L1; EXPRESSION; PLEOMORPHIC CARCINOMA; CELL INFILTRATION; POOR-PROGNOSIS; SINGLE-ARM; EFFICACY; CHEMOTHERAPY; INHIBITORS;

D O I：

10.1177/17588359241249041

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pulmonary sarcomatoid carcinoma (PSC), a rare subtype of non-small cell lung cancer, is highly malignant and has a poor prognosis. Treatments for PSC are presently limited. Traditional treatments provide fewer benefits to PSC patients and are associated with early recurrence and metastasis. Surgical intervention is the preferred option for early-stage PSC patients, whereas chemotherapy, radiotherapy, immunotherapy, and other targeted therapies are recommended for advanced PSC patients. Targeted therapy is only effective in a small number of PSC patients. The initial efficacy of immune checkpoint inhibitors has been acceptable in patients with advanced PSC; therefore, much attention on related biomarkers has been sought. This article aimed to review the research progress of PSC immunotherapy and related diagnostic and prognostic biomarkers in recent years. Advances in immunotherapy for pulmonary sarcomatoid carcinomaPulmonary sarcomatoid carcinoma (PSC), a rare subtype of non-small cell lung cancer (NSCLC), is highly malignant and has a poor prognosis. Traditional treatments provide fewer benefits to PSC patients and are associated with early recurrence and metastasis. Targeted therapy is only effective in a small number of PSC patients. The initial efficacy of immune checkpoint inhibitors (ICIs) has been acceptable in patients with advanced PSC, therefore, much attention on related biomarkers has been sought. This article aimed to review the research progress of PSC immunotherapy and related diagnostic and prognostic biomarkers in recent years.

引用

页数：13

共 69 条

[1] Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis [J].

Babacan, Nalan A. ;

Pina, Isabel B. ;

Signorelli, Diego ;

Prelaj, Arsela ;

Garassino, Marina C. ;

Tanvetyanon, Tawee .

CLINICAL LUNG CANCER, 2020, 21 (05) :E456-E463

[2] Therapeutic Targeting of the Tumor Microenvironment [J].

Bejarano, Leire ;

Jordao, Marta J. C. ;

Joyce, Johanna A. .

CANCER DISCOVERY, 2021, 11 (04) :933-959

[3] Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC) [J].

Bodor, J. Nicholas ;

Boumber, Yanis ;

Borghaei, Hossein .

CANCER, 2020, 126 (02) :260-270

[4] Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227 [J].

Brahmer, Julie R. ;

Lee, Jong-Seok ;

Ciuleanu, Tudor-Eliade ;

Bernabe Caro, Reyes ;

Nishio, Makoto ;

Urban, Laszlo ;

Audigier-Valette, Clarisse ;

Lupinacci, Lorena ;

Sangha, Randeep ;

Pluzanski, Adam ;

Burgers, Jacobus ;

Mahave, Mauricio ;

Ahmed, Samreen ;

Schoenfeld, Adam J. ;

Paz-Ares, Luis G. ;

Reck, Martin ;

Borghaei, Hossein ;

O'Byrne, Kenneth J. ;

Gupta, Ravi G. ;

Bushong, Judith ;

Li, Li ;

Blum, Steven I. ;

Eccles, Laura J. ;

Ramalingam, Suresh S. .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) :1200-+

[5] CD8+ tumor-infiltrating lymphocytes as a novel prognostic biomarker in lung sarcomatoid carcinoma, a rare subtype of lung cancer [J].

Chen, Jiewei ;

He, Qingmei ;

Liu, Jun ;

Xiao, Yongbo ;

Xiao, Canhua ;

Chen, Keming ;

Xie, Dan ;

Zhang, Xinke .

CANCER MANAGEMENT AND RESEARCH, 2018, 10 :3505-3511

[6] Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor [J].

Chen, Xinru ;

Zhang, Yu ;

Lu, Jiabin ;

Xu, Chunwei ;

Liang, Jianzhong ;

Wang, Fang ;

Sun, Wenyong ;

Fang, Sangao ;

Yuan, Jingping ;

Wang, Huijuan ;

Wang, Hui ;

Liu, Xuewen ;

Chen, Likun .

TRANSLATIONAL ONCOLOGY, 2017, 10 (02) :115-120

[7] Pembrolizumab - emerging treatment of pulmonary sarcomatoid carcinoma: A case report [J].

Cimpeanu, Emanuela ;

Ahmed, Jibran ;

Zafar, Wahib ;

DeMarinis, Adreana ;

Bardarov, Svetoslav S. ;

Salman, Shamim ;

Bloomfield, Dennis .

WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (01) :97-102

[8] Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma [J].

Domblides, Charlotte ;

Leroy, Karen ;

Monnet, Isabelle ;

Mazieres, Julien ;

Barlesi, Fabrice ;

Gounant, Valerie ;

Baldacci, Simon ;

Mennecier, Bertrand ;

Toffart, Anne-Claire ;

Audigier-Valette, Clarisse ;

Doucet, Ludovic ;

Giroux-Leprieur, Etienne ;

Guisier, Florian ;

Ricordel, Charles ;

Molinier, Olivier ;

Perol, Maurice ;

Pichon, Eric ;

Robinet, Gilles ;

Templement-Grangerat, Dorine ;

Ruppert, Anne-Marie ;

Rabbe, Nathalie ;

Antoine, Martine ;

Wislez, Marie .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (05) :860-866

[9]

Ettinger DS., 2019, NCCN guidelines insights: non-small cell lung cancer

[10] High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets [J].

Fallet, V. ;

Saffroy, R. ;

Girard, N. ;

Mazieres, J. ;

Lantuejoul, S. ;

Vieira, T. ;

Rouquette, I. ;

Thivolet-Bejui, F. ;

Ung, M. ;

Poulot, V. ;

Schlick, L. ;

Moro-Sibilot, D. ;

Antoine, M. ;

Cadranel, J. ;

Lemoine, A. ;

Wislez, M. .

ANNALS OF ONCOLOGY, 2015, 26 (08) :1748-1753

← 1 2 3 4 5 6 7 →